1. accompanying diseases other than covid-19 with an expected survival time of less than 12 months. 2. previous treatment with any sars-cov-2-convalescent plasma 3. in the opinion of the clinical team, progression to death is imminent and inevitable within the next 48 hours, irrespective of the provision of treatment 4. interval \> 72 hours since start of ventilation support 5. not considered eligible for extracorporeal oxygenation support (even in case of severe ards according to berlin classification with horovitz-index \< 100 mg hg) 6. chronic obstructive lung disease (copd), stage 4 7. lung fibrosis with uip pattern in ct und severe emphysema 8. chronic heart failure nyha \>= 3 and/or pre-existing reduction of left ventricular ejection fraction to ≤ 30% 9. shock of any type requiring ≥ 0.5 µg/kg/min noradrenaline (or equivalent) or requiring more than two types of vasopressor medication for more than 8 hours 10. liver cirrhosis child c 11. liver failure: bilirubin \> 5xuln and elevation of alt /ast (at least one \>10xuln). 12. any history of adverse reactions to plasma proteins 13. known deficiency of immunoglobulin a 14. pregnancy 15. breastfeeding women 16. volume overload until sufficiently treated 17. participation in another clinical trial with an investigational medicinal product

1. accompanying diseases other than covid-19 with an expected survival time of less than 12 months. 2. previous treatment with any sars-cov-2-convalescent plasma 3. in the opinion of the clinical team, progression to death is imminent and inevitable within the next 48 hours, irrespective of the provision of treatment 4. interval \> 72 hours since start of ventilation support 5. not considered eligible for extracorporeal oxygenation support (even in case of severe ards according to berlin classification with horovitz-index \< 100 mg hg) 6. chronic obstructive lung disease (copd), stage 4 7. lung fibrosis with uip pattern in ct und severe emphysema 8. chronic heart failure nyha \>= 3 and/or pre-existing reduction of left ventricular ejection fraction to ≤ 30% 9. shock of any type requiring ≥ 0.5 µg/kg/min noradrenaline (or equivalent) or requiring more than two types of vasopressor medication for more than 8 hours 10. liver cirrhosis child c 11. liver failure: bilirubin \> 5xuln and elevation of alt /ast (at least one \>10xuln). 12. any history of adverse reactions to plasma proteins 13. known deficiency of immunoglobulin a 14. pregnancy 15. breastfeeding women 16. volume overload until sufficiently treated 17. participation in another clinical trial with an investigational medicinal product

accompanying diseases other than covid-19 with an expected survival time of less than 12 months. previous treatment with any sars-cov-2-convalescent plasma in the opinion of the clinical team, progression to death is imminent and inevitable within the next 48 hours, irrespective of the provision of treatment interval > 72 hours since start of ventilation support not considered eligible for extracorporeal oxygenation support (even in case of severe ards according to berlin classification with horovitz-index < 100 mg hg) chronic obstructive lung disease (copd), stage 4 lung fibrosis with uip pattern in ct und severe emphysema chronic heart failure nyha >= 3 and/or pre-existing reduction of left ventricular ejection fraction to ≤ 30% shock of any type requiring ≥ 0.5 µg/kg/min noradrenaline (or equivalent) or requiring more than two types of vasopressor medication for more than 8 hours liver cirrhosis child c liver failure: bilirubin > 5xuln and elevation of alt /ast (at least one >10xuln). any history of adverse reactions to plasma proteins known deficiency of immunoglobulin a pregnancy breastfeeding women volume overload until sufficiently treated participation in another clinical trial with an investigational medicinal product

accompanying diseases other than covid-19 with an expected survival time of less than 12 months. previous treatment with any sars-cov-2-convalescent plasma in the opinion of the clinical team, progression to death is imminent and inevitable within the next 48 hours, irrespective of the provision of treatment interval > 72 hours since start of ventilation support not considered eligible for extracorporeal oxygenation support (even in case of severe ards according to berlin classification with horovitz-index < 100 mg hg) chronic obstructive lung disease (copd), stage 4 lung fibrosis with uip pattern in ct und severe emphysema chronic heart failure nyha >= 3 and/or pre-existing reduction of left ventricular ejection fraction to ≤ 30% shock of any type requiring ≥ 0.5 µg/kg/min noradrenaline (or equivalent) or requiring more than two types of vasopressor medication for more than 8 hours liver cirrhosis child c liver failure: bilirubin > 5xuln and elevation of alt /ast (at least one >10xuln). any history of adverse reactions to plasma proteins known deficiency of immunoglobulin a pregnancy breastfeeding women volume overload until sufficiently treated participation in another clinical trial with an investigational medicinal product

1. accompanying diseases other than covid-19 with an expected survival time of less than 12 months. 2. previous treatment with any sars-cov-2-convalescent plasma 3. in the opinion of the clinical team, progression to death is imminent and inevitable within the next 48 hours, irrespective of the provision of treatment 4. interval > 72 hours since start of ventilation support 5. not considered eligible for extracorporeal oxygenation support (even in case of severe ards according to berlin classification with horovitz-index < 100 mg hg) 6. chronic obstructive lung disease (copd), stage 4 7. lung fibrosis with uip pattern in ct und severe emphysema 8. chronic heart failure nyha >= 3 and/or pre-existing reduction of left ventricular ejection fraction to ≤ 30% 9. shock of any type requiring ≥ 0.5 µg/kg/min noradrenaline (or equivalent) or requiring more than two types of vasopressor medication for more than 8 hours 10. liver cirrhosis child c 11. liver failure: bilirubin > 5xuln and elevation of alt /ast (at least one >10xuln). 12. any history of adverse reactions to plasma proteins 13. known deficiency of immunoglobulin a 14. pregnancy 15. breastfeeding women 16. volume overload until sufficiently treated 17. participation in another clinical trial with an investigational medicinal product

1. accompanying diseases other than covid-19 with an expected survival time of less than 12 months. 2. previous treatment with any sars-cov-2-convalescent plasma 3. in the opinion of the clinical team, progression to death is imminent and inevitable within the next 48 hours, irrespective of the provision of treatment 4. interval > 72 hours since start of ventilation support 5. not considered eligible for extracorporeal oxygenation support (even in case of severe ards according to berlin classification with horovitz-index < 100 mg hg) 6. chronic obstructive lung disease (copd), stage 4 7. lung fibrosis with uip pattern in ct und severe emphysema 8. chronic heart failure nyha >= 3 and/or pre-existing reduction of left ventricular ejection fraction to ≤ 30% 9. shock of any type requiring ≥ 0.5 µg/kg/min noradrenaline (or equivalent) or requiring more than two types of vasopressor medication for more than 8 hours 10. liver cirrhosis child c 11. liver failure: bilirubin > 5xuln and elevation of alt /ast (at least one >10xuln). 12. any history of adverse reactions to plasma proteins 13. known deficiency of immunoglobulin a 14. pregnancy 15. breastfeeding women 16. volume overload until sufficiently treated 17. participation in another clinical trial with an investigational medicinal product